Sanofi-aventis Acquires TargeGen to Strengthen its Oncology Pipeline

By Staff Editor

Pharma Deals Review: Vol 2010 Issue 7 (Table of Contents)

Published: 2 Sep-2010

DOI: 10.3833/pdr.v2010.i7.1361     ISSN: 1756-7874

Section: Mergers & Acquisitions



Sanofi-aventis is acquiring TargeGen, a developer of small molecule kinase inhibitors for the treatment of various types of cancers, in a deal potentially valued at US$560 M...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details